CompePharma View: Trust the raise you can check this quarter, not the target you can't

Two kinds of earnings release

Read this week's third-quarter releases side by side and the useful divide is not big versus small, or branded versus devices. It is tense. Some companies let the quarter make the argument. Others ask the reader to accept a future that the quarter does not yet show.

Tarsus is in the first group. Xdemvy net product sales reached a record $194.6 million, up about 64% year-over-year, and the company has passed one million bottles dispensed and $1 billion in cumulative net sales in three years. Xeris is in the first group too. Total revenue rose 44% to $107 million, Recorlev grew 93% to more than $71 million, and management raised full-year guidance to $395 million to $405 million. iRhythm raised both its 2026 revenue guidance, to $890 million to $895 million, and its adjusted EBITDA margin guidance, to 15.5% to 16.0%, on what it called volume-led growth.

In each case the claim about tomorrow rests on a number you can check today.

Where the future tense does the work

United Therapeutics told investors it is "entering a period of extraordinary growth." The quarter it reported showed revenue up four percent to $832.5 million from $799.5 million, a gain of $33 million. That is a record and a large, durable business. It is also a distance from the adjective. Inspire is more candid: it delivered sequential growth, said U.S. performance beat expectations, and described 2027 as the planned return to growth. Its new Category I CPT codes for single-lead hypoglossal nerve stimulation do not take effect until January 1, 2028. Collegium sits between the two: record revenue of $216.3 million, up 3%, with JORNAY PM up 24% and a first full quarter of AZSTARYS. It reaffirmed guidance rather than raising it.

None of this is a criticism of the pipelines or the coding changes. It is a point about how much weight each narrative can bear.

The case for patience, and why it only goes so far

The strongest counter-argument is that the current quarter is a poor yardstick for companies investing in what comes next. Large revenue bases grow slowly by arithmetic, so 4% on $800 million-plus is not the same as 64% on a younger launch. Reimbursement fixes like Inspire's coding change take years and cannot be rushed. Judging a company by this quarter alone would punish exactly the long-horizon work this industry is built on.

That is fair, and it explains why the fast-growing names look easier. But it argues for patience, not for suspending scrutiny. The most instructive release this season is Xeris, which raised its 2030 outlook to more than $1 billion, up from approximately $750 million. It did so in the same release in which it raised its 2026 guidance. The long-range target came with a near-term raise that management will have to deliver within months. A distant number is cheap to move. Moving it alongside a number you must hit soon is what makes it credible.

What this means for how pharma talks

Executives are being tempted to widen the gap between what they report and what they promise. Investors and partners will increasingly sort companies by whether that gap is bridged by evidence or by adjectives. If your growth is modest, say so plainly and let the pipeline stand on its own merits. If your outlook is ambitious, tie it to a near-term commitment that can fail visibly.

— The Editors, CompePharma